Pharmaceutical drug opportunity assessment
Our insights and recommendations will give you the confidence to make the right strategic decisions at the early stages of commercialisation
Product development is the lifeblood of the pharmaceutical industry. But evaluating the wealth of potential opportunities at the early stages of drug discovery and commercialisation is fraught with uncertainty. We can help you to assess and evaluate opportunities systematically and comprehensively, using a range of qualitative research and quantitative research methods to answer questions such as:
- Where are the unmet needs in the marketplace?
- What is the viability of this product concept?
- What is the size of the market opportunity?
- What is the likely demand for this product?
- Where are the growth markets?
- What is the competitive landscape?
- What should our portfolio look like?
Custom research offerings include:
- Market access consulting
- Demand assessments and forecasting
- Concept evaluations
- Market and product analysis
- Portfolio planning
- Competitor analysis
- How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
The challenge: Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful…read more »How we assessed the access potential of a new product in order to develop a successful launch strategy
Our client had two regimens in clinical development for the front-line treatment of an oncology condition using a breakthrough product; and planned to release outcomes data at key industry events throughout the year.read more »Using demand assessment techniques to evaluate the market landscape and product opportunity
The challenge:Our client wanted to evaluate the potential of two treatments which would offer efficacy and side effects similar to those of biologics in atopic dermatitis. Therefore our client needed to understand more about the US and German market landscape in moderate-severe atopic dermatitis and how these advanced treatments might fit into the treatment algorithim when they are launched, as well as the potential drivers…read more »How the opportunity for a product treating a rare haematology disease in Emerging Markets was evaluated using a multi-stakeholder approach
Our client wanted to determine how to maximise the commercial opportunities for a product indicated for a rare disease in a range of emerging marketsread more »
- Some example case studiesHow we conducted ethnography research to enhance new product development
The challengeThe majority of stoma patients in developing emerging markets such as India and Indonesia use external bags that are domestically manufactured or imported. We conducted research which gave internal stakeholders the necessary direction for developing a new product concept. The solutionEthnography research in the form of participant observations was conducted with 10 patients in each market who had a permanent colostomy procedure. The ethnography…read more »How we used ethnography to capture behavioural insights
The challengeHaemophilia A & B markets are highly competitive and cluttered where HCPs and patients perceive similar efficacy and safety across available products. Our client wanted to inform the design of an improved infusion device to differentiate and deliver a better experience. The challenge was to identify deeper insights from behavioural observation (beyond claimed/ stated experience) to differentiate user experience across various devices and identify…read more »How we helped our client to evaluate early biosimilar user experience
The challenge: Our client wanted to evaluate early user experience for physicians and patients across Europe of a newly launched biosimilar in an autoimmune disease. The results were needed to better understand drivers and barriers of prescribing/using biosimilars (vs. biologics) and suitable patient types to develop more targeted communication material. The solution: We opted for qualitative telephone interviews to reach a dispersed and small target…read more »